Valeo Pharma and Zambon announce the approval of Onstryv® (safinamide) for Canada

- Valeo Pharma and Zambon previously announced a partnership which grants Valeo Pharma exclusive Canadian rights to commercialize safinamide (known as Onstryv® in Canada and Xadago® in the rest of the world.)

- New treatment option for estimated 100,000 Canadians living with Parkinson's Disease

- Safinamide has been launched in 13 European countries, Switzerland and the U.S.A, and has recently been approved in Australia.

January 15, 2019 –Zambon S.p.A., an international pharmaceutical company strongly committed to the central nervous system (CNS) therapeutic area, and Valeo Pharma Inc., a specialty pharmaceutical company dedicated to commercializing innovative prescription products in Canada, today announce the approval of Onstryv® (safinamide) for thetreatment of Parkinson’s Disease in Canada.

Under the terms of the agreement with Zambon, Valeo Pharma is responsible for all regulatory, quality, sales and marketing, and distribution activities in Canada.

“There is a growing need for new treatments to manage Parkinson’s Disease and Onstryv®provides an important option for patients that require better control of their symptoms. Welook forward to launching the first new oral treatment for Parkinson’s Disease in over adecade to Canadian patients in need of a new therapeutic choice” said Steve Saviuk, ChiefExecutive Officer of Valeo.

Valeo Pharma expects the Canadian launch of safinamide to occur during the first half of 2019.

Roberto Tascione, CEO of Zambon said “The approval of safinamide in Canada is a stepforward for patients who need new treatment options for Parkinson’s Disease. Our mission is to make this medication available to as many PD patients worldwide as possible.”

Parkinson’s Disease is a progressive neurological disease involving the loss of dopamine- producing neurons in the brain. While tremors are the best known symptom, Parkinson’sDisease also causes slowed movement, rigid muscles, impaired posture and balance, and speech and writing difficulties. An estimated 100,000 Canadians are affected, and the number of patients is expected to grow significantly over the next thirty years as the population continues to age.